New study aims to predict fertility problems in young men after cancer treatment
NCT ID NCT07612943
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 1,000 young men (ages 15-39) diagnosed with cancer to understand how treatments affect their fertility and hormone levels over time. Researchers will collect medical history, semen samples, and blood tests before and after therapy to identify who is at risk for infertility or low testosterone. The goal is to create personalized care plans to help survivors manage their reproductive health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Multi-center study on European AYA patient cohorts. Prospective observational multicohort study including male AYA cancer patients enrolled after a diagnosis of primary cancer and followed at 1, 2 and 3 years post diagnosis. The cohort database will be maintained to allow additional follow-up \>3 years after reconsent to allow for further longitudinal research. The subjects will be recruited at \~16 European Centres with expertise in oncofertility.
- Ages
-
15 to 39 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects with male internal and external genitalia * Age at cancer diagnosis 15-39 years old * Subjects planned to or having received oncologic treatment * Subjects able to provide semen sample * Information available on cancer treatment and medical history * Patients (or parents in case of minors) who signed informed consent Exclusion Criteria: * individuals presenting with relapse or secondary cancers at time of inclusion * subjects who were not treated with oncological treatment * subjects who underwent bilateral orchiectomy * patients with a diagnosis of azoospermia or testicular failure previously to cancer diagnosis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Two-Drug combo aims to stall advanced breast cancer
- The hidden handshake that decides whether an embryo implants
- Blood thinner flush could boost tumor biopsy success